menu
    • menu
    [{"orgOrder":0,"company":"Dalriada Drug Discovery","sponsor":"ATAI Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Discovery","graph3":"Dalriada Drug Discovery","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Dalriada Drug Discovery \/ ATAI Life Sciences","highestDevelopmentStatusID":"2","companyTruncated":"Dalriada Drug Discovery \/ ATAI Life Sciences"},{"orgOrder":0,"company":"Mydecine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Discovery","graph3":"Mydecine","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Mydecine \/ Inapplicable","highestDevelopmentStatusID":"2","companyTruncated":"Mydecine \/ Inapplicable"}]

    Find Clinical Drug Development Pipelines & Deals | PipelineProspector

    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Mydecine

                            Canada arrow
                            IFT FIRST
                            Not Confirmed

                            Mydecine

                            Canada arrow
                            IFT FIRST
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Discovery

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Mydecine Achieves Innovative Supercomputing Artificial Intelligence Modeling in Psychedelic Drug Development E...

                            Details : The new serotonin receptor model (5-HT2A) will allow the Company to rapidly increase drug analysis promoting near-term patent filings for novel psychedelic molecules for the treatment of mental health disorder.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            October 01, 2022

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Discovery

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Dalriada Drug Discovery

                            Canada arrow
                            IFT FIRST
                            Not Confirmed

                            Dalriada Drug Discovery

                            Canada arrow
                            IFT FIRST
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Discovery

                            Sponsor : ATAI Life Sciences

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Dalriada Drug Discovery to Collaborate with atai Life Sciences' New Platform Company to Discover Next-Generati...

                            Details : This strategic collaboration with atai Life Sciences will focus on the creation of small molecule therapies by building on the mechanism of action of psychedelic and related compounds.

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            January 27, 2022

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Discovery

                            Sponsor : ATAI Life Sciences

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth